Why did “ Biotech is in a dark place ” resonate with so many of you? Because it’s true! Collectively, we’re all frustrated ...

The heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

It's also important for your practitioner to know certain details about your medical history that may affect whether azithromycin is the best antibiotic for you. Tell them if you have ever had an ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Before the public offering, the biotech had mapped out its capital needs up to 2028, according to CEO Jeff Finer, M.D., Ph.D. “We actually had plenty of cash to get through 2025,” Finer told ...

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead drug candidate, ersodetug, for the treatment of congenital ...

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

Moleculin Biotech stock surged on high volume after FDA guidance allowed a 10% reduction in its Phase 3 trial for Annamycin. The MIRACLE Phase 3 study's first unblinding at 45 subjects is expected ...